Welcome to the fifth and final episode in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?” Transactions involving digital assets are becoming an increasing focus for pharmaceutical companies. In this series, life sciences industry M&A veteran and Sterling Technology board advisor John Easton discusses how these differ from traditional life science deals, and what both parties should look out for to increase the chances of deal success, mitigate risks, and avoid failure.
In previous episodes, we’ve covered key areas of difference between traditional life science transactions and the new world of digital dealmaking including corporate culture, information governance, defining and valuing the asset, and due diligence. In this final conversation, we pull these strands together and discuss how they influence transaction structure and terms – which both parties must agree on to bring any deal to a successful conclusion. You can also learn more by downloading our report which accompanies this podcast series.
